E2F2/PI3K/AKT signaling pathway

The E2F2/Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) axis connects growth factor signaling to the decision to divide. Ligand binding at receptors such as the EGFR or the insulin receptor recruits Phosphatidylinositol 3-kinase (PI3K), which phosphorylates membrane PIP2 to PIP3, creating docking sites that bring AKT to the plasma membrane where PDK1 and mTORC2 phosphorylate it. The relationship between AKT and Mtor runs in both directions and is easy to state wrongly: mTOR complex 2 lies upstream, phosphorylating AKT at Ser473 to complete its activation, while AKT lies upstream of complex 1, relieving its inhibition by phosphorylating TSC2 and PRAS40. Active AKT also phosphorylates FOXO transcription factors to exclude them from the nucleus, and inactivates pro-apoptotic effectors, so the same signal simultaneously drives protein synthesis, alters glucose and lipid metabolism, and suppresses apoptosis.

E2F2 is where this converges on the cell cycle. Growth signaling raises cyclin D, whose CDK4/6 complexes phosphorylate retinoblastoma protein and release the E2F family — E2F2 among the activating members — to transcribe the genes required for S phase. The pathway therefore does not merely favor survival; it removes the restriction point that would otherwise hold a cell out of the cycle in the absence of external signals.

Dysregulation runs in both directions. Constitutive activation, most often through PIK3CA mutation or PTEN loss, supports proliferation and survival in cancer, and the resulting dependence on cyclin D–CDK4/6 is what CDK4/6 inhibitors exploit downstream. Deficient signaling contributes instead to metabolic disease — insulin resistance and the cognitive decline associated with type 2 diabetes — and in hepatocellular disease, hepatitis C virus-mediated perturbation of PI3K/AKT through multiple viral and host mechanisms, including microRNA regulation, contributes to glycolipid metabolic disorder. Because the pathway integrates growth factors, hormones and nutrient availability, therapeutic strategies pull in opposite directions by context: inhibition in oncology, restoration in metabolic disease.